Last reviewed · How we verify
RO7567132 and Atezolizumab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
RO7567132 and Atezolizumab (RO7567132 and Atezolizumab) — Hoffmann-La Roche.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| RO7567132 and Atezolizumab TARGET | RO7567132 and Atezolizumab | Hoffmann-La Roche | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- RO7567132 and Atezolizumab CI watch — RSS
- RO7567132 and Atezolizumab CI watch — Atom
- RO7567132 and Atezolizumab CI watch — JSON
- RO7567132 and Atezolizumab alone — RSS
Cite this brief
Drug Landscape (2026). RO7567132 and Atezolizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/ro7567132-and-atezolizumab. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab